Compare Lululemon Athletica Inc (LULU) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lululemon Athletica Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Lululemon Athletica Inc trades at $116.62 (market cap $13.25B), while Regeneron Pharmaceuticals Inc trades at $674.87 (market cap $70.47B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 5.3× Lululemon Athletica Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Lululemon Athletica Inc pays none. Which is the better fit depends on your goals.
| LULU | REGN | |
|---|---|---|
Market Cap | $13.25B | $70.47B |
Sector | Consumer Cyclical | Health |
52-Week High | $224.03 | $812.27 |
52-Week Low | $105.43 | $545.46 |
Enterprise Value | $13.87B | $64.42B |
Dividend Yield | — | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lululemon trades at $116.63, up 0.26% today, amid bearish technical signals but strong fundamentals. The stock shows consistent earnings beats, with Q1 2026 EPS of $1.69 exceeding the $1.67 estimate. Revenue grew to $10.59B in 2025, with a net income margin of 17.13%. Recent news includes a $30M investment in nylon recycling startup Syntetica and resolution of a proxy battle with founder Chip Wilson, boosting shareholder confidence.
The outlook is mixed: valuation metrics like a P/E of 9.45 and EV/EBITDA of 5.41 suggest potential upside to the $129.29 consensus target, but technical bearishness and competitive pressures pose risks. Investors may find value in robust profitability and strategic initiatives, though macroeconomic headwinds and brand controversies require monitoring.
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lululemon Athletica Inc
Lululemon Athletica Inc. designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls. Lululemon offers pants, shorts, tops, and jackets for both leisure and athletic activities such as yoga and running. The company also sells fitness accessories, such as bags, yoga mats, and equipment. Lululemon sells its products through more than 600 company-owned stores in 18 countries, e-commerce, outlets, and wholesale accounts. The company was founded in 1998 and is based in Vancouver, Canada.
Read more on LULU →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
